Effect of 1,5-anhydroglucitol levels on culprit plaque rupture in diabetic patients with acute coronary syndrome

Gong Su1*, Ming-Xi Gao1, Gen-Ling Shi1, Xi-Xi Dai1, Wei-Feng Yao1, Tao Zhang2 and Shao-Wei Zhuang3*

Abstract

Background: Postprandial hyperglycemia was reported to play a key role in established risk factors of coronary artery diseases (CAD) and cardiovascular events. Serum 1,5-anhydroglucitol (1,5-AG) levels are known to be a clinical marker of short-term postprandial glucose (PPG) excursions. Low serum 1,5-AG levels have been associated with occurrence of CAD. However, the relationship between 1,5-AG levels and coronary plaque rupture has not been fully elucidated. The aim of this study was to evaluate 1,5-AG as a predictor of coronary plaque rupture in diabetic patients with acute coronary syndrome (ACS).

Methods: A total of 144 diabetic patients with ACS were included in this study. All patients underwent intravascular ultrasound examination, which revealed 49 patients with plaque rupture and 95 patients without plaque rupture in the culprit lesion. Fasting blood glucose (FBG), hemoglobin A1c (HbA1c) and 1,5-AG levels were measured before coronary angiography. Fasting urinary 8-iso-prostaglandin F2α (8-iso-PGF2α) level was measured and corrected by creatinine clearance.

Results: Patients with ruptured plaque had significantly lower serum 1,5-AG levels, longer duration of diabetes, higher HbA1c and FBG levels than patients without ruptured plaque in our study population. In multivariate analysis, low 1,5-AG levels were an independent predictor of plaque rupture (odds ratio 3.421; P = 0.005) in diabetic patients with ACS. The area under the receiver-operating characteristic curve for 1,5-AG (0.658, P = 0.002) to predict plaque rupture was superior to that for HbA1c (0.587, P = 0.087). Levels of 1,5-AG were significantly correlated with urinary 8-iso-prostaglandin F2α levels (r = −0.234, P = 0.005).

Conclusions: Serum 1,5-AG may identify high risk for coronary plaque rupture in diabetic patients with ACS, which suggests PPG excursions are related to the pathogenesis of plaque rupture in diabetes.

Keywords: 1,5-Anhydroglucitol, Plaque rupture, Acute coronary syndrome, Diabetes, Intravascular ultrasound

Background

Acute coronary syndromes (ACS), including ST-elevation myocardial infarction (STEMI) and Non-ST-elevation acute coronary syndromes (NSTEMI), are a common cause of morbidity and mortality in individuals with diabetes. Autopsy data and intravascular imaging studies have showed that ACS results from spontaneous plaque rupture or erosion and subsequent thrombosis [1–3]. A meta-analysis, based on optical coherence tomography findings, showed the rate of plaque ruptures is 70.4% in...
STEMI patients, 55.6% in NSTEMI patients and 39.1% in unstable angina patients, respectively [4]. In an analysis of lesions from patients after sudden coronary death, ruptured plaque is recognized to be responsible for the most of cases of acute coronary thrombi [5]. Diabetic patients are at a high risk for cardiovascular events for having more vulnerable features in both culprit and non-culprit lesions compare to patients without diabetes [6]. Many researchers are attempting to find out what factors could affect coronary plaque rupture in diabetic patients for preventing critical outcomes.

Serum 1,5-anhydroglucitol (1,5-AG) level is a clinical marker to better reflect short-term postprandial hyperglycemia and glycemic variability (GV) than do hemoglobin A1c (HbA1c) level [7]. Therefore, 1,5-AG levels may be associated with cardiovascular complications in diabetes. Indeed, some studies have reported that 1,5-AG levels are bound up with cardiovascular disease [8, 9]. Several clinical studies showed that 1,5-AG levels had utility to predict cardiovascular events in study population [10–12]. However, the association between 1,5-AG levels and coronary plaque rupture in diabetic patients with ACS is unclear. Intravascular ultrasound (IVUS) can provide detailed, high-quality tomographic images to detect plaque rupture in vivo [13]. In the present study, we investigated whether any relation exists between serum 1,5-AG level and ruptured plaque in culprit lesion identified by IVUS in diabetic patients with ACS.

**Methods**

**Patient population and study design**

This is a prospective observational study. We included 220 type 2 diabetes mellitus (T2DM) patients with ACS, who were admitted to Shanghai General Hospital Baoshan Branch and Beijing Anzhen Hospital between December 2018 and July 2019. All enrolled patients were admitted and underwent coronary angiography and IVUS in the culprit vessel. Patients with any of the following were excluded from the study: (1) totally occlusive lesions, (2) restenosis after stenting, (3) previous coronary artery bypass graft surgery, (4) severe heart failure (NYHA functional class III or above), renal failure (creatinine clearance < 30 mL/min), hepatic insufficiency, or infectious disease, (5) HbA1c > 8%, (6) taking sodium-glucose cotransporter 2 inhibitor, and (7) insufficient clinical data. A total of 144 patients were included for analysis after excluding 76 patients who meeting the exclusion criteria. 49 patients had coronary plaque rupture in culprit lesion diagnosed by IVUS. ACS consisted of ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI) and unstable angina pectoris, which were defined according to 2013 ACCF/AHA guideline for the management of STEMI and 2014 ACC/AHA guideline for NSTEMI. T2DM was diagnosed according to the American Diabetes Association criteria or medical history and the use of insulin or glucose-lowering medication. Hypertension was defined as systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg or treatment with oral antihypertensive drugs. Hyperlipidemia was diagnosed according to the modified National Cholesterol Education Program-Adult Treatment Panel III. The study protocol was approved beforehand by the Medical Ethics Committee of Shanghai General Hospital Baoshan Branch and the Medical Ethics Committee of Beijing Anzhen Hospital, and the procedures followed were in accordance with the institutional guidelines. The study complied with the Declaration of Helsinki, and informed consent was obtained from all patients.

**IVUS imaging protocol and analysis**

All patients were performed with coronary angiography by standard Judkins technique. IVUS examination was performed using an IVUS system (iLAB™ Ultrasound Imaging System, Boston Scientific, USA) and a 40 MHz intravascular catheter (OptiCross™, Boston Scientific, USA) before any intervention. The IVUS catheter was advanced into the culprit vessel more than 10 mm beyond the culprit lesion and withdrawn at a pullback speed of 0.5 mm/s automatically. In this study, a culprit lesion was defined as the lesion related to the clinical event, as identified by both coronary angiography and electrocardiogram findings. A ruptured plaque was defined as the plaque contained a cavity that communicated with the lumen with an overlying residual fibrous cap fragment. A fragmented and loosely adherent plaque without a distinct cavity and without a fibrous cap fragment was not considered as a plaque rupture [14]. IVUS quantitative analysis was performed by two independent experienced interventional cardiologists who were blinded to the patients’ clinical information according to the criteria of the American College of Cardiology Clinical Expert Consensus Document on IVUS.

**Laboratory measurement**

We collected blood samples and urine samples from patients after overnight fasting. Samples were stored at − 80 °C prior to analysis. Serum levels of 1,5-AG were measured by a colorimetric method (Nippon Kayaku, Tokyo, Japan) using a Lana 1,5-AG auto liquid automatic analyzer (ICA-BM 8060, JEOL Ltd., Tokyo, Japan). Serum concentration of hemoglobin A1c (HbA1c) was determined by high-performance liquid chromatographic method (Tosoh HLC-723G7; Tosoh Corporation, Tokyo, Japan). The urinary 8-iso-prostaglandin F2α (8-iso-PGF2α)
levels were measured by a competitive enzyme-linked immunosorbent assay (Cayman Chemical, Ann Arbor, MI, USA) and corrected by creatinine clearance. The plasma concentration of fasting blood glucose (FBG), creatinine, total cholesterol (TC), high-density lipoprotein cholesterol (HDL-c), low-density lipoprotein cholesterol (LDL-c), triglyceride (TG), the high-sensitivity C-reactive protein (hs-CRP), N-terminal pro-brain natriuretic peptide (NT-proBNP), and troponin I (TnI) were measured. The non-HDL-c level was calculated as the TC level minus the HDL-c level.

Statistical analysis
All statistical analyses were performed by using SPSS for Windows 24.0 (SPSS Inc, Chicago, IL, USA). All data were tested for normal distribution with the Kolmogorov–Smirnov test. Data are presented as mean with standard deviation (SD) for continuous distributed variables, frequencies and percentages for categorical variables, and median with 25% and 75% percentiles for abnormal distributed parameters. Differences between two groups were assessed by using the t-tests, Chi square, and Mann–Whitney rank analysis. Correlation between continuous variables was determined by Pearson correlation coefficients. Univariate and multivariate logistic regression analyses were performed in tow models to identify independent predictors for ruptured culprit plaque in study population. 1,5-AG level was included as a continuous variable in Model 1 and as a categorized variable (categorized into tertiles) in Model 2. The predictive value of 1,5-AG and HbA1c for the presence of ruptured plaque in culprit lesion was calculated by constructing receiver-operating characteristic (ROC) curves. A value of P < 0.05 was considered statistically significant.

Results
Clinical characteristics of patients
During the study period, 220 diabetic patients with ACS underwent CAG and IVUS. We excluded 16 patients with restenosis after stenting, 15 patients with insufficient IVUS data, 5 patients with severe heart failure, 8 patients with renal failure, 14 patients without 1,5-AG data, and 18 patients with other data loss. Finally, a total of 144 patients were enrolled into the present study. Among of all subjects, 49 patients had culprit plaque rupture detected by IVUS (Rupture group), 95 patients had not (Non-rupture group) (Fig. 1). Compared to patients of non-rupture group, those patients with ruptured plaque had significantly lower 1,5-AG levels (10.5 ± 5.5 vs. 14.1 ± 7.7 μg/mL, P = 0.005), longer duration of diabetes [median (interquartile range): 4.2 (2.0, 5.2) vs. 2.5 (1.2, 4.8) years, P = 0.009], higher FBG (8.1 ± 3.0 vs. 7.1 ± 2.0 mmol/L, P = 0.023), HbA1c (7.2 ± 0.5 vs. 7.0 ± 0.6%, P = 0.025), and non-HDL-c [4.39 (3.63, 4.99) vs. 3.83 (3.43, 4.36) mmol/L, P = 0.006] levels. Patients with plaque rupture also had higher hs-CRP [2.46 (1.61,
5.23) vs. 1.22 (0.84, 4.01), \( P = 0.014 \) and urinary 8-iso-PGF\(_{2\alpha}\) (141.9 ± 67.2 vs. 116.1 ± 71.6 pmol/mmolCr, \( P = 0.038 \)) levels than patients without plaque rupture. No significant differences were observed between two groups in terms of age, gender, hypertension, hyperlipidemia, body mass index (BMI), blood pressure, eGFR, and medicine treatments (Table 1).

### Angiographic and IVUS results

Angiographic findings and IVUS analysis were summarized in Table 2. Culprit lesions of all 144 enrolled patients were evaluated by IVUS. Plaque rupture was observed in 49 patients (34%). There were no significant differences in culprit lesion location and three-vessel disease between plaque rupture and non-rupture groups. IVUS data showed there were not significant differences in lesion volume, length, plaque burden, external elastic membrane cross-sectional areas, lumen cross-sectional areas, plaque plus media cross-sectional areas, and remodeling index between patients with and without plaque rupture.

### Relationship between 1,5-AG level and plaque rupture

We performed univariate and multivariate analysis to determine independent predictors for plaque rupture in culprit lesion. For multivariable regression analysis in model 1, variables (age, gender, current smoking, duration of diabetes, BMI, left ventricular ejection fraction, estimated glomerular filtration rate, systolic blood pressure, diastolic blood pressure, triglycerides, high-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, white blood cell, hs-CRP) were included in the model. The independent predictors for plaque rupture were duration of diabetes (years), BMI (kg/m\(^2\)), LVEF (%), eGFR (mL/min/1.73 m\(^2\)), and 1,5-AG (µg/mL) (Table 1).

### Table 1 Clinical characteristics in the study population

| Variables | Rupture | Non-rupture | \( P \) value |
|-----------|---------|-------------|---------------|
| \( n \)   | 49      | 95          |               |
| Age (years) | 59±9    | 60±10       | 0.474         |
| Males     | 28 (57.1) | 62 (65.3)  | 0.340         |
| Current smoking | 34 (69.4) | 51 (53.7)  | 0.069         |
| Hypertension | 36 (73.5) | 65 (68.4)  | 0.531         |
| Hyperlipidemia | 32 (65.3) | 58 (61.1)  | 0.617         |
| Duration of diabetes (years) | 4.2 (2.0, 5.2) | 2.5 (1.2, 4.8) | 0.009         |
| BMI (kg/m\(^2\)) | 26.4±3.6 | 25.6±3.5  | 0.110         |
| LVEF (%) | 59.5±8.3 | 62.2±9.2   | 0.092         |
| eGFR (mL/min/1.73 m\(^2\)) | 84.6±28.6 | 88.0±30.8 | 0.491         |
| SBP (mmHg) | 130±13  | 131±16      | 0.612         |
| DBP (mmHg) | 76±8    | 77±10       | 0.638         |
| TG (mmol/L) | 1.93 (1.12, 2.13) | 1.72 (0.94, 1.88) | 0.079         |
| HDL-C (mmol/L) | 0.96 (0.82, 1.24) | 1.02 (0.91, 1.23) | 0.314         |
| Non-HDL-C (mmol/L) | 4.39 (3.63, 4.99) | 3.83 (3.43, 4.36) | 0.006         |
| WBC (10⁹/L) | 7.3±1.6 | 7.2±1.7     | 0.958         |
| hs-CRP (mg/dL) | 2.46 (1.61, 5.23) | 1.22 (0.84, 4.01) | 0.014         |
| NT-proBNP | 390 (155, 960) | 362 (105, 890) | 0.413         |
| Tnl | 1.20 (0.11, 5.12) | 0.91 (0.03, 2.62) | 0.228         |
| Urinary 8-iso-PGF\(_{2\alpha}\) (pmol/mmolCr) | 141.9±67.2 | 116.1±71.6 | 0.038         |
| FBG (mmol/L) | 8.1±3.0 | 7.1±2.0     | 0.023         |
| HbA\(_1c\) (%) | 7.2±0.5 | 7.0±0.6     | 0.025         |
| 1,5-AG (µg/mL) | 10.5±5.5 | 14.1±7.7   | 0.005         |
| Medications on admission | Aspirin | Statins | ACEI/ARB | Oral antidiabetic drugs | Insulin |
| | 36 (73.5) | 27 (55.1) | 25 (51.0) | 31 (63.3) | 16 (32.7) |
| | 71 (74.7) | 62 (65.3) | 52 (54.7) | 64 (67.4) | 32 (33.7) |
| Data are given as number (percentage) for categorical variables and mean ± standard deviation or median (IQR) for continuous variables.  
BMI, body mass index; LVEF, left ventricular ejection fraction; eGFR, estimated glomerular filtration rate; SBP, systolic blood pressure; DBP, diastolic blood pressure; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; non-HDL-C, non-high-density lipoprotein cholesterol; WBC, white blood cell; hs-CRP, high-sensitivity C-reactive protein; NT-proBNP, N-terminal pro-brain natriuretic peptide; Tnl, troponin I; 8-iso-PGF\(_{2\alpha}\), 8-iso-prostaglandin F\(_{2\alpha}\); FBG, fasting blood glucose; HbA\(_1c\), hemoglobin A\(_1c\); 1,5-AG, 1,5-anhydroglucitol; ACEI/ARB, angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker.
Table 2 Culprit lesion characteristics assessed by angiography and intravascular ultrasound

| Variables            | Rupture | Non-rupture | P value |
|----------------------|---------|-------------|---------|
| n                    | 49      | 95          |         |
| Angiographic analysis|         |             |         |
| Culprit lesion       |         |             | 0.694   |
| LM                   | 2 (2.6) | 5 (5.3)     |         |
| LAD                  | 20 (34.2)| 38 (40.4)  |         |
| LCX                  | 9 (15.8)| 16 (16.0)   |         |
| RCA                  | 18 (47.4)| 36 (38.3)  |         |
| Lesion location      |         |             | 0.579   |
| Ostial               | 2 (2.6) | 6 (6.4)     |         |
| Proximal             | 18 (34.2)| 33 (35.1)  |         |
| Mild                 | 23 (52.6)| 44 (46.8)  |         |
| Distal               | 6 (10.5)| 12 (11.7)   |         |
| 3-vessel disease     | 21 (42.9)| 33 (34.7)  | 0.340   |
| IVUS analysis        |         |             |         |
| EEM CSA (mm²)        | 20.9 ± 6.4| 19.4 ± 5.4 | 0.106   |
| Lumen CSA (mm²)      | 4.3 ± 1.4| 4.2 ± 1.0   | 0.585   |
| P&M CSA (mm²)        | 16.6 ± 5.9| 15.1 ± 5.4 | 0.164   |
| Plaque burden (%)    | 78.6 ± 8.0| 76.8 ± 8.3 | 0.209   |
| Length (mm)          | 19.0 ± 5.4| 18.6 ± 6.8 | 0.688   |
| Volume (mm³)         | 135.7 ± 55.3| 127.4 ± 58.5| 0.402   |
| Remodeling index     | 1.01 ± 0.15| 0.97 ± 0.17| 0.196   |

Data are given as number (percentage) for categorical variables and mean ± standard deviation.

LM left main coronary artery, LAD left anterior descending coronary artery, LCX left circumflex coronary artery, RCA right coronary artery, IVUS intravascular ultrasound, EEM external elastic membrane, CSA cross-sectional area, P&M plaque plus media.

1,5-AG levels and coronary plaque rupture

1,5-AG is a naturally occurring 1-deoxy form of glucose. As glucose levels surpass the renal threshold for glucosuria (generally around 10 mmol/L), 1,5-AG is excreted in the urine leading to a rapid reduction in serum levels [16]. Therefore, poor glycemic control is associated with low, rather than high, serum 1,5-AG levels. Unlike HbA1c, 1,5-AG values are not affected by mean erythrocyte age and can accurately reflect the glycemic control in hemolytic patients [17]. On the other hand, 1,5-AG levels can also reflect the status of gestational DM in pregnant women and may anticipate the development of gestational DM [18]. In the present study, we used IVUS to identify plaque rupture.
in culprit lesion of diabetic patients with ACS and found that the 1,5-AG levels were significantly lower in patients with ruptured plaque than in patients without ruptured plaque. Meanwhile, patients with ruptured plaque had higher HbA1c, FBG, and non-HDL-c levels compared to patients with non-ruptured plaque. This result indicates that diabetic patients with ruptured culprit plaque had worse glycometabolic and lipidemic disorders. In accordance with some recent in vivo studies [19, 20], no differences were observed for age and sex between the patients with or without culprit plaque rupture. In model 1 and model 2, univariate and multivariate logistic regression analyses showed that low 1,5-AG, high non-HDL-c levels and current smoking were independent predictors of plaque rupture of culprit lesion in diabetic patients with ACS. These results indicate that poor glycemic control and dyslipidemia may be associated with the coronary plaque rupture in diabetes. Sheng et al. reported that increased duration of DM combined with higher HbA1c levels influences culprit-plaque characteristics in patients with DM who suffer AMI [21]. In the present study, patients with ruptured plaque had longer duration of DM and higher HbA1c levels than patients without ruptured plaque. The level of HbA1c > 7% is associated with an increased risk of culprit plaque rupture. Moreover, the ROC curve analysis showed 1,5-AG displayed more significant value in predicting plaque rupture than HbA1c. Preliminary data have shown that 1,5-AG could be expected to best reflect postprandial hyperglycemia in moderately controlled patients and was more sensitive and specific than HbA1c [22]. Furthermore, as PPG increments are the major contributors to GV in T2DM, 1,5-AG may be particularly suited for monitoring

Table 3  Independent predictors for ruptured culprit plaque

|                  | Model 1 Univariate |                     | Model 2 Univariate |                     |
|------------------|---------------------|---------------------|---------------------|---------------------|
|                  | OR (95% CI)         | P value             | OR (95% CI)         | P value             |
| Age (≥ 65 years) | 0.869 (0.414, 1.824) | 0.710               |                     |                     |
| Female           | 1.305 (0.608, 2.801) | 0.494               |                     |                     |
| Current smoking  | 2.278 (0.961, 5.398) | 0.062               | 2.647 (1.018, 6.883) | 0.046               |
| Duration of diabetes | 1.059 (0.991, 1.130) | 0.090               |                     |                     |
| Body mass index  | 1.102 (0.978, 1.245) | 0.111               |                     |                     |
| LVEF             | 0.968 (0.932, 1.006) | 0.095               |                     |                     |
| TG               | 1.353 (0.961, 1.906) | 0.084               |                     |                     |
| Non-HDL-C        | 1.904 (1.233, 2.940) | 0.004               | 1.983 (1.236, 3.183) | 0.005               |
| hs-CRP           | 1.007 (0.940, 1.080) | 0.837               |                     |                     |
| 1,5-AG           | 0.914 (0.856, 0.976) | 0.007               | 0.916 (0.852, 0.985) | 0.018               |
| FBG              | 1.176 (1.019, 1.357) | 0.026               |                     |                     |
| HbA1c            | 1.989 (1.083, 3.653) | 0.027               |                     |                     |
| Urinary 8-iso-| 1.005 (1.000, 1.010) | 0.042               |                     |                     |

Model 1: Age, duration of diabetes, body mass index, LVEF, TG, non-HDL-C, hs-CRP, 1,5-AG, FBG, HbA1c and urinary 8-iso-PGF2α were included as continuous variables.
Model 2: All variables were included as categorized variables

LVEF left ventricular ejection fraction, TG triglycerides, non-HDL-C non-high-density lipoprotein cholesterol, hs-CRP high-sensitivity C-reactive protein, 1,5-AG 1,5-anhydroglucitol, FBG fasting blood glucose, HbA1c hemoglobin A1c, 8-iso-PGF2α 8-iso-prostaglandin F2α
postprandial hyperglycemic excursions [23]. Unlike HbA1c, 1,5-AG is not affected by hypoglycemia. As a result, 1,5-AG appears to differentiate patients with extensive PPG excursions despite having similar HbA1c levels. Selvin et al. reported that patients with low 1,5-AG levels had an increased risk of coronary artery disease, stroke, heart failure, and death compared to patients with high 1,5-AG levels [10]. Takahashi et al. reported that low and exacerbated levels of 1,5-AG are associated with cardiac mortality in ACS patients [11]. The study of Fujiwara et al. showed that 1,5-AG was associated with the presence of de novo coronary artery disease in both well-controlled diabetic and non-diabetic patients [8]. Low 1,5-AG level had been found to be associated with coronary artery calcification, which may be related to the coronary plaque vulnerability [24, 25]. The current study is the first to report that 1,5-AG levels are significantly associated with coronary plaque rupture in diabetic patients with ACS. These findings may partly explain the results of previous studies that 1,5-AG levels were associated with cardiovascular outcomes and support the hypothesis that PPG excursions is strongly associated with the atherosclerotic vulnerable plaque process.

**Mechanism for PPG excursions affecting plaque rupture**

Although the identified role of PPG excursions in the pathogenesis of plaque rupture has not been clarified, oxidative stress, inflammation and endothelial dysfunction may be involved in the process. It was demonstrated that glucose excursions increased oxidative stress than chronic hyperglycemia in T2DM. Ceriello et al. showed that targeting postprandial hyperglycemia has the potential to reduce oxidative stress [26]. We have recently reported that glycemic variability, a component of which is PPG excursions, was significantly correlated with oxidative stress measured as urinary 8-iso-PGF2α, which is a key mechanism for the development of atherosclerotic plaques in humans. The present study showed that serum 1,5-AG level, but not HbA1c, was strongly correlated with urinary 8-iso-PGF2α level in diabetic patients with ACS. This is in accordance with the

---

**Fig. 2** Receiver-operating characteristic curves of 1,5-AG and HbA1c levels to predict coronary plaque rupture in diabetic patients with ACS. The areas under the curve of 1,5-AG (1/x) and HbA1c levels were 0.658 (0.563–0.752, P = 0.002) and 0.587 (0.490–0.684, P = 0.087), respectively. 1,5-AG, 1,5-anhydro-D-glucitol; HbA1c, hemoglobin A1c.
previous report of Kohata et al. that 1,5-AG is the strong correlate of oxidative stress in patients with T2DM [28], and it suggests that PPG excursions can be more important than mean glucose to induce oxidative stress in diabetes. It has been demonstrated that oxidative stress plays a key role in atherosclerotic plaque progression [29]. Our previous study showed that increased urinary 8-iso-PGF$_{2\alpha}$ levels were closely associated with greater absolute and percent necrotic core volumes of coronary lesions in diabetic patients [30]. In a pathological study by Nishibe et al., 8-iso-PGF$_{2\alpha}$ was found enriched in coronary plaque specimens especially from vulnerable patients, suggesting a crucial role of free radicals in the formation of vulnerable plaques [31]. Yura et al. reported that 8-iso-PGF$_{2\alpha}$ per se could stimulate endothelin-1 mRNA and protein expression in bovine aortic endothelial cells [32]. Endothelin-1 may cause the stimulation of vascular smooth muscle proliferation and formation of macrophage-rich atherosclerotic plaques. In the study of Esposito et al., the results suggested that acute hyperglycemia, and not sustained elevation of blood glucose levels, could exaggerate inflammation by an oxidative mechanism [33]. Teraguchi et al. reported that dynamic glucose fluctuation was positively and significantly associated with CD14$^{\text{bright}}$ CD16$^+$ monocytes levels and might be related to coronary plaque rupture in patients with acute myocardial infarction [34]. All these findings suggest that postprandial hyperglycemic excursions may be involved in progression and destabilization of coronary plaques through the preferential increase in oxidative stress, proinflammatory cytokines, and endothelial dysfunction. Optimizing PPG excursions management may be helpful to prevent the rupture of coronary plaque in diabetic patients.

**Study limitations**

Several study limitations should be considered in the interpretation of the results. First, the sample size was relatively small, so that it may have influenced the results and the statistical analyses. Second, because we evaluated only limited patients who underwent IVUS and didn’t meet any exclusion criteria, our results could have been affected by selection bias and cannot be generalized to all patients. Third, the assessment of plaque rupture was made by IVUS in this study. Although it has been demonstrated that IVUS can provide detailed,
high-quality tomographic images to detect plaque rupture, it might be likely that some plaque ruptures were undetected. More detailed plaque morphology could be obtained by combining high definition IVUS with optical coherence tomography (OCT), virtually increasing accuracy for plaque rupture detection. Finally, this is an observational study. The observational nature of analysis means that we cannot infer causality in the associations we have demonstrated. Future longitudinal and prospective studies are needed to address these issues.

Conclusions

Serum 1,5-AG displayed significant value in predicting culprit plaque rupture in diabetic patients with ACS. This suggests that PPG excursions are related to the pathogenesis of plaque rupture in diabetes. The manipulation of PPG excursions may provide a potential therapeutic target for preventing plaque rupture.

Abbreviations

1,5-AG: 1,5-Anhydroglucitol; PPG: Postprandial glucose; GV: Glycemic variability; ACS: Acute coronary syndrome; T2DM: Type 2 diabetes mellitus; IVUS: Intravascular ultrasound; 8-iso-PGF2α: 8-Iso-prostaglandin F2α; FBG: Fasting blood glucose; HbA1c: Hemoglobin A1c; BMI: Body mass index; non-HDL-C: Non-high-density lipoprotein cholesterol; hs-CRP: High-sensitivity C-reactive protein; NT-proBNP: N-terminal pro-brain natriuretic peptide; TNF: Tumor necrosis factor; LVEF: Left ventricular ejection fraction.

Acknowledgements

We convey thanks to the professional technical assistance from the laboratory technicians at the Clinical Laboratory Center. The authors thank the volunteer patients for their participation, and the study nurses for their skills and devotion to the patient care.

Authors’ contributions

GS and SWZ participated in the design of the study. GS and TZ participated in the exercise protocols. MXG, GLS and XXD performed laboratory measurements. MXG and TZ participated in data collection. GS performed the statistical analysis and drafted the manuscript. SWZ participated in revising the manuscript. All authors read and approved the final manuscript.

Funding

This work was supported by a key grant from Outstanding Clinical Discipline Project of Shanghai Pudong (PWgy 2018-05). This work was supported by a key grant from Beijing Health Special Foundation (JING 15-10). The funder was not involved in any study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

The study was conducted in accordance with the Declaration of Helsinki, and was approved by the Medical Ethics Committee of Shanghai General Hospital Baoshan Branch and the Medical Ethics Committee of Beijing Anzhen Hospital. All participants provided written informed consent.

Consent for publication

Not applicable.

Competing interests

The authors of the manuscript do not have any closely related papers or manuscripts that have been submitted or published elsewhere and declare that they do not have any competing interests.

Author details

1 Department of Cardiovascular Medicine, Shanghai General Hospital Baoshan Branch, No. 101 Tongtai North Road, Baoshan District, Shanghai 200040, China. 2 Center of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China. 3 Department of Cardiovascular Medicine, The Seventh People’s Hospital, Shanghai University of Traditional Chinese Medicine, No. 358 Gaogiaoqizhong Road, Pudong District, Shanghai 200137, China.

Received: 10 March 2020 Accepted: 26 May 2020

Published online: 30 May 2020

References

1. Stefanadis C, Antoniou CK, Tsiachris D, Pietri P. Coronary atherosclerotic vulnerable plaque: current perspectives. J Am Heart Assoc. 2017;6(3):e005543.
2. Saia F, Komukai K, Capodanno D, Sirbu V, Musumeci G, Bocuzzi G, et al. Eroded versus ruptured plaques at the culprit site of stent: in vivo pathological features and response to primary PCI. JACC. Cardiovascular Imaging. 2015;8(5):566–75.
3. Higuma T, Soeda T, Abe N, Yamada M, Yokoyama H, Shibutani S, et al. A combined optical coherence tomography and intravascular ultrasound study on plaque rupture, plaque erosion, and calcified nodule in patients with st-segment elevation myocardial infarction: incidence, morphologic characteristics, and outcomes after percutaneous coronary intervention. JACC. Cardiovascular Imaging. 2015;8(9):1166–76.
4. Iannaccone M, Quadri G, Taha S, D’Ascenzo F, Montefusco A, Omede P, et al. Prevalence and predictors of culprit plaque rupture at OCT in patients with coronary artery disease: a meta-analysis. Eur Heart J Cardiovascular Imaging. 2016;17(10):1128–37.
5. Virmari R, Kolodge FD, Burke AP, Farb A, Schwartz SM. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2000;20(5):1262–75.
6. Sugiyama T, Yamamoto E, Bryniarski K, Xing L, Fracassi F, Lee H, et al. Coronary plaque characteristics in patients with diabetes mellitus who presented with acute coronary syndromes. J Am Heart Assoc. 2018;7(14):e009245.
7. Kim WJ, Park CY. 1,5-Anhydroglucitol in diabetes mellitus. Endocrine. 2013;43(1):33–40.
8. Fujiiwa T, Yoshida M, Yamada H, Tsukui T, Nakamura T, Sakakura K, et al. Lower 1,5-anhydroglucitol is associated with de novo coronary artery disease in patients at high cardiovascular risk. Heart Vessels. 2015;30(4):669–76.
9. Ikeda N, Hara H, Hiroi Y. 1,5-Anhydro-o-glucitol predicts coronary artery disease prevalence and complexity. J Cardiol. 2014;64(4):297–301.
10. Selvin E, Rawlings A, Lustey P, Maruthur N, Pankow JS, Steffes M, et al. Association of 1,5-anhydroglucitol with cardiovascular disease and mortality. Diabetes. 2016;65(1):201–8.
11. Takahashi S, Shimada K, Miyachi K, Miyazaki T, Sai E, Ogita M, et al. Low and exacerbated levels of 1,5-anhydroglucitol are associated with cardiovascular events in patients after first-time elective percutaneous coronary intervention. Cardiovasc Diabetol. 2016;15(1):145.
12. Ouchi S, Shimada K, Miyazaki T, Takahashi S, Sugita Y, Shimizu M, et al. Low 1,5-anhydroglucitol levels are associated with long-term cardiac mortality in acute coronary syndrome patients with hemoglobin A1c levels less than 7.0. Cardiovasc Diabetol. 2017;16(1):151.
13. Ma T, Zhou B, Hsiai TK, Shung KK. A review of intravascular ultrasound-based multimodal intravascular imaging: the synergistic approach to characterizing vulnerable plaques. Ultrasound Imaging. 2016;38(5):314–31.
14. Tian J, Ren X, Vergallo R, Xing L, Yu H, Jia H, et al. Distinct morphological features of ruptured culprit plaque for acute coronary events compared to those with silent rupture and thin-capped fibroatheroma: a combined optical coherence tomography and intravascular ultrasound study. J Am Coll Cardiol. 2014;63(21):2209–16.
15. Hong YJ, Jeong MH, Choi YH, Ko JS, Lee MG, Kang WY, et al. Plaque characteristics in culprit lesions and inflammatory status in diabetic acute coronary syndrome patients. JACC. Cardiovasc Imaging. 2009;2(3):339–49.
16. Akamutsu T, Akamutsu M, Fukuzawa N, Yamamoto T, Akamutsu H. Urinary excretion of 1,5-anhydro-o-glucitol accompanying glucose excretion in diabetic patients. Diabetologia. 1988;31(11):831–5.
17. Kinoshita N, Komiya T, Tokuhiro S, Matsumura Y, Matsu H, Koga M. Hemolysis causes a decrease in HbA1c level but not in glycated albumin or 1,5-anhydroglucitol level. Scand J Clin Lab Invest. 1979;39(6):377–80.
18. Lorenzo-Almorós A, Hang T, Peiró C, Soriano-Guillén L, Esguejo J, Tuñón J, et al. Predictive and diagnostic biomarkers for gestational diabetes and its associated metabolic and cardiovascular diseases. Cardiovasc Diabetol. 2019;18(1):140.
19. Kim HO, Kim CJ, Kim W, Cho JM, Soeda T, Takano M, et al. Relative risk of plaque erosion among different age and sex groups in patients with acute coronary syndrome. J Thromb Thrombolysis. 2020;49(3):352–9.
20. Niccoli G, Montone RA, Di Vito L, Gramegna M, Refaat H, Scalone G, et al. Impact of glucose fluctuation and monocyte subsets on coronary plaque rupture and intact fibrous cap assessed by optical coherence tomography portend different outcomes in patients with acute coronary syndrome. Eur Heart J. 2019;60(3):569–76.
21. Dungan KM, Buse JB, Largay J, Kelly MM, Buset EA, Kato S, et al. 1,5-anhydroglucitol measured by continuous glucose monitoring system among people with type 2 diabetes: an optical coherence tomography study. Cardiovasc Diabetol. 2019;18(1):136.
22. Wang Y, Zhang YL, Wang YP, Lei CH, Sun ZL. A study on the association of serum 1,5-anhydro-glucitol and glycated albumin with oxidative stress in type 2 diabetes mellitus patients: a cross-sectional study. Diabetes Ther. 2020;11(3):655–65.
23. Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M, et al. Increased inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation. 2008;106(16):2067–72.
24. Teraguchi I, Imanishi T, Ogi Y, Yamamoto T, Ori M, Shiono Y, et al. Impact of glucose fluctuation and monocyte subsets on coronary plaque rupture. Nutr Metab Cardiovasc Dis. 2014;24(3):309–14.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.